Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Phase 1

Completed

Conditions: Stem Cell Transplantation
Leukemia

Interventions: Drug: Plerixafor
Drug: Filgrastim
Drug: Fludarabine
Drug: Busulfan
Procedure: Allogeneic blood stem cell transplant
Drug: ATG (Thymoglobulin)

First Posted Date: 2009-01-14

Last Posted Date: 2020-10-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT00822770

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes
Lymphoma
Leukemia
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: alemtuzumab
Biological: graft-versus-tumor induction therapy
Biological: rituximab
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methotrexate
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation

First Posted Date: 2009-01-08

Last Posted Date: 2013-12-18

Lead Sponsor: Northside Hospital, Inc.

Target Recruit Count: 36

Registration Number: NCT00818961

Locations: 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

Conditions: Stem Cell Transplantation
Leukemia

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Thymoglobulin
Drug: Azacitidine
Procedure: Stem Cell Transplant

First Posted Date: 2008-12-22

Last Posted Date: 2021-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00813124

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: pegfilgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: fludarabine phosphate
Genetic: cytogenetic analysis
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: protein expression analysis
Other: flow cytometry
Other: laboratory biomarker analysis

First Posted Date: 2008-12-22

Last Posted Date: 2023-04-06

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 52

Registration Number: NCT00812669

Locations: 🇮🇪
St. James's Hospital, Dublin, Ireland
🇮🇪
University College Hospital, Galway, Ireland
🇮🇪
Waterford Regional Hospital, Waterford, Ireland

and more 4 locations

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2008-12-11

Last Posted Date: 2011-05-17

Lead Sponsor: Institut Paoli-Calmettes

Target Recruit Count: 82

Registration Number: NCT00806767

Locations: 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Phase 1

Conditions: Non-Hodgkins Lymphoma

Interventions: Drug: Rituximab
Drug: 90Y ibritumomab tiuxetan (Zevalin)
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Non myeloablative allogeneic stem cell transplantation

First Posted Date: 2008-12-11

Last Posted Date: 2008-12-11

Lead Sponsor: Maisonneuve-Rosemont Hospital

Target Recruit Count: 20

Registration Number: NCT00807196

Locations: 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2008-12-05

Last Posted Date: 2011-05-16

Lead Sponsor: Institut Paoli-Calmettes

Target Recruit Count: 48

Registration Number: NCT00802568

Locations: 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Phase 1

Terminated

Conditions: Neuroblastoma
Immunodeficiencies
Anemia
Leukemia
Lymphoma

Interventions: Radiation: Total Body Irradiation
Drug: Alemtuzumab
Drug: Busulfan
Drug: Melphalan
Drug: Fludarabine
Drug: Phenytoin
Drug: Rabbit Antithymocyte Globulin
Drug: Cyclophosphamide
Drug: Horse Antithymocyte Globulin
Drug: Thiotepa

First Posted Date: 2008-12-04

Last Posted Date: 2019-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 1

Registration Number: NCT00801931

Locations: 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Phase 1

Completed

Conditions: Hodgkins Disease
Non-Hodgkin's Lymphoma

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Anti-Thymocyte Globulin

First Posted Date: 2008-12-04

Last Posted Date: 2019-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 30

Registration Number: NCT00802113

Locations: 🇺🇸
Children's Memorial Hospital in Chicago, Chicago, Illinois, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 3 locations

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Myelodysplastic Syndrome With Excess Blasts
t(8;21)
High Risk Myelodysplastic Syndrome
Inv(16)
t(16;16)
Untreated Adult Acute Myeloid Leukemia
de Novo Myelodysplastic Syndrome

Interventions: Drug: Cytarabine
Drug: Decitabine
Biological: Filgrastim-sndz
Drug: Fludarabine Phosphate
Drug: Gemtuzumab Ozogamicin
Drug: Idarubicin
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-12-03

Last Posted Date: 2024-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 270

Registration Number: NCT00801489

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy